Kolexia
Maslah Nabih Pharmacien
Maslah Nabih
Pharmacien
Hôpital Saint-Louis
Paris, France
62 Activités
557 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myéloprolifératifs Leucémie aigüe myéloïde Polyglobulie primitive essentielle Polyglobulie Myélofibrose primitive Thrombose Syndromes myélodysplasiques Tumeurs hématologiques Leucémies

Collaborateurs

Voir plus
Cassinat Bruno
Cassinat Bruno
Hôpital Saint-Louis, Paris, France
Kiladjian Jean-Jacques
Kiladjian Jean-Jacques
Hôpital Saint-Louis, Paris, France
Giraudier Stephane
Giraudier Stephane
Hôpital Saint-Louis, Paris, France
Benajiba Lina
Benajiba Lina
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Servier
1 collaboration(s)
Dernière en 2023
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
American journal of hematology   25 février 2024
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
American journal of hematology   26 janvier 2024
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Blood cancer journal   04 janvier 2024
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Leukemia   27 décembre 2023
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).
Leukemia   11 juillet 2023
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France   07 juin 2023
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.
Leukemia   31 mars 2023
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
British journal of haematology   22 décembre 2022
Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
Annual Meeting Abstracts 2022   15 novembre 2022
Reduced MDM2 and MDM4 Protein, but Not mRNA, Expression Is Associated with More Severe Disease in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomoncytic Leukemia (CMML)
Annual Meeting Abstracts 2022   15 novembre 2022